Get the Stockscreener App
206.11
0.98%
-2.05
Pre-market:
205.55
-0.56
-0.27%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $206.11, with a volume of 4.48M.
It is down -0.98% in the last 24 hours and down -1.31% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$208.16
Open:
$208.97
24h Volume:
4.48M
Relative Volume:
0.63
Market Cap:
$364.56B
Revenue:
$62.82B
Net Income/Loss:
$3.62B
P/E Ratio:
101.38
EPS:
2.0331
Net Cash Flow:
$17.82B
1W Performance:
+4.26%
1M Performance:
-1.31%
6M Performance:
-4.92%
1Y Performance:
+5.12%
1-Day Range:
$205.83
$209.51
1-Week Range:
$190.75
$214.87
52-Week Range:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Glenwood Academy students, AbbVie scientists team up for science fair projects - The Lansing Journal
Want to Collect a High Dividend Every Month? Invest in These 3 Stocks - The Motley Fool
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week - Investing News Network
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
AbbVie presents IBD data at digestive disease conference By Investing.com - Investing.com Canada
Steroid use fell to 7% in AbbVie Crohn's study after 52 weeks - Stock Titan
Leukemia Therapeutics Market to Reach US$ 31.37 Billion by 2033 - openPR.com
ABBV Maintained by Evercore ISI Group -- Price Target Raised to $236 - GuruFocus
AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook - The Globe and Mail
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold? - TradingView
Federated Hermes MDT Market Neutral ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AVIP BlackRock Advantage Large Cap Value Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
Sarofim Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC - MarketBeat
Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV - MarketBeat
Heritage Wealth Management, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
Wellment Financial's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Reports Q1 Revenue Growth Despite Earnings Miss - GuruFocus
AB Sustainable Thematic Balanced Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat - MarketBeat
Strs Ohio Has $181.81 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
PFA Pension Forsikringsaktieselskab Buys New Shares in AbbVie Inc. $ABBV - MarketBeat
Robertson Stephens Wealth Management LLC Acquires 34,246 Shares of AbbVie Inc. $ABBV - MarketBeat
Horizon Investments LLC Has $31.65 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at DZ Bank - MarketBeat
OMC Financial Services LTD's AbbVie Inc(ABBV) Holding History - GuruFocus
Benjamin Edwards Inc. Has $77.83 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance - MarketBeat
AbbVie (NYSE:ABBV) Stock Price Down 2.2%Here's What Happened - MarketBeat
Thrivent Moderately Aggressive Allocation Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried - WSJ
ABBV Reiterated by Guggenheim -- Price Target Maintained at $249 - GuruFocus
10 Health Care Stocks With Whale Alerts In Today's SessionAbbVie (NYSE:ABBV), AtaiBeckley (NASDAQ:ATAI - Benzinga
U.S. Large Cap Growth Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (NYSE: ABBV) Posts Q1 Revenue of $15B, Raises Guidance - Value The Markets
AbbVie Stock Beats Q1 Estimates as Skyrizi Hits $4.5B in a Single Quarter - TIKR.com
AbbVie option and FDA feedback reshape Aldeyra (Nasdaq: ALDX) drug plans - Stock Titan
Netflix, Cisco, Zoom And A Health Care Stock On CNBC's 'Final Trades'Cisco Systems (NASDAQ:CSCO) - Benzinga
SNS Financial Group LLC Has $2.97 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Sells 8,094 Shares of AbbVie Inc. $ABBV - MarketBeat
Fifth Third Bancorp Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Danske Bank A S Has $267.24 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts? - Yahoo Finance
U.S. Growth Trust's AbbVie Inc(ABBV) Holding History - GuruFocus
FDA filing for investigational alopecia areata treatment lifts AbbVie stock 3.65% - Traders Union
AbbVie stock jumps 3.65% as Q1 2026 earnings call announcement boosts sentiment - Traders Union
Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT - Insider Monkey
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):